New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTTGT, STEL, EXPE, PG, PSX, MYL, CME, ACAT, OI, HBAN, AB, LAZOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AllianceBernstein (AB) upgraded to Equal Weight from Underweight at Morgan Stanley... CME Group (CME) upgraded to Outperform from Market Perform at Raymond James... Expedia (EXPE) upgraded to Buy from Hold at Benchmark Co.... Expedia (EXPE) upgraded to Outperform from Market Perform at Raymond James... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Citigroup... Mylan (MYL) upgraded to Buy from Hold at Canaccord... StellarOne (STEL) upgraded to Strong Buy from Outperform at Raymond James... Owens-Illinois (OI) upgraded to Buy from Neutral at BofA/Merrill... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Target (TGT) upgraded to Buy from Neutral at Buckingham... Arctic Cat (ACAT) upgraded to Strong Buy from Buy at Felti... Proctor and Gamble (PG) upgraded to Outperform from Underperform at CLSA... Lazard (LAZ) upgraded to Neutral from Sell at Rochdale.
News For AB;CME;EXPE;HBAN;MYL;STEL;OI;PSX;TGT;ACAT;PG;LAZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 22, 2015
16:17 EDTLAZLazard raises quarterly dividend by 17% to 35c per share
Subscribe for More Information
16:00 EDTMYLOptions Update; April 22, 2015
iPath S&P 500 VIX Short-Term Futures down 22c to 21.30. Option volume leaders: AAPL TSLA TWTR MCD FB PBR AMZN KMI MYL C according to Track Data.
15:50 EDTLAZ, PGNotable companies reporting before tomorrow's open
Subscribe for More Information
15:12 EDTPGProcter & Gamble technical comments before earnings
Subscribe for More Information
15:10 EDTPGEarnings Watch: Procter & Gamble to report Q3 results after forex warnings
Subscribe for More Information
12:04 EDTMYLTeva may need to raise Mylan bid above $90 per share, analysts say
Subscribe for More Information
10:21 EDTHBANHuntington Bancshares: NIM pressure to remain headwind until interest rates rise
Says committed to "smart, accretive" acquisitions. Says focused on managing expenses to attain positive operating leverage for the year. Says "optimistic" about ongoing economic improvement in footprint, on national level. Says loan pipelines are strong, will be selective in growing commercial real estate portfolio. Says execution of goals not dependent on interest rate increase. Says NIM pressure to remain headwind until interest rates start moving up. Comments made on the Q1 earnings conference call. Huntington Bancshares is down 1.88% to $10.96 in morning trading.
09:56 EDTMYLMylan planning firmer offer for Perrigo, CNBC's Faber reports
Mylan (MYL) is planning to announce a firmer takeover offer for Perrigo (PRGO) that will include financing commitments and ticking fees, CNBC's David Faber reports, citing people familiar with the matter. It is unclear if the offer will include a higher buyout price of $205 per share, Faber added.
09:44 EDTMYLSources: Mylan planning new offer for Perrigo, CNBC's Faber says
Subscribe for More Information
09:08 EDTMYLTeva price target raised to $75 from $64 at Argus
Subscribe for More Information
08:43 EDTMYLHostile bids carry low success rates, says Leerink
Subscribe for More Information
08:42 EDTMYLMylan likely to seek higher offer from Teva, says Bernstein
after Teva (TEVA) offered to buy Mylan (MYL) for $82 per share, Bernstein expects Mylan to seek an offer closer to $90. The firm also expects Mylan to seek shared management and perhaps some protection for its employees. Bernstein expects Teva to attempt to convince Mylan shareholders of the merits of its offer and Mylan to attempt to convince Perrigo (PRGO) shareholders of the merits of its offer and its own shareholders of the risks associated with the Teva deal. Bernstein keeps Outperform ratings on Teva and Mylan.
08:31 EDTMYLTeva files for Hart Scott Rodino notification regarding proposed Mylan purchase
Teva Pharmaceutical Industries (TEVA) announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. Teva’s proposal for Mylan implies a total equity value of approximately $43 billion and an enterprise value of approximately $50 billion. The Teva Board and management team are committed to consummating a transaction as soon as possible. The acquisition proposal would provide Teva stockholders with very attractive strategic and financial benefits and Mylan stockholders with a substantial premium and immediate value for their shares, as well as the opportunity to participate in the significant upside potential of the combined company – one that would transform the global generics space and leverage it to hold a unique leadership position in the pharmaceutical industry. Teva has carefully studied the regulatory aspects of a combination of Teva and Mylan, in conjunction with its advisors. Teva is confident that it would be able to structure a transaction that would not contain material impediments to closing and that it can determine and promptly implement divestitures, as necessary, to gain regulatory clearances. Teva intends to work cooperatively with antitrust authorities and expects that the proposed transaction can be completed by year-end 2015. Teva’s proposal provides Mylan stockholders with a more attractive alternative to Mylan’s proposed acquisition of Perrigo Company plc (PRGO), as announced on April 8, 2015, as well as to Mylan on a standalone basis. Teva’s proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylan’s press release regarding its unsolicited proposal for Perrigo, and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva and Mylan. Barclays and Greenhill & Co. are serving as financial advisors to Teva. Kirkland & Ellis LLP and Tulchinsky Stern Marciano Cohen Levitski & Co are serving as legal counsel to Teva, with De Brauw Blackstone Westbroek N.V. and Loyens & Loeff N.V. acting as legal advisors in the Netherlands.
08:29 EDTHBANHuntington Bancshares expects to deliver positive operating leverage in 2015
Subscribe for More Information
07:27 EDTMYLPiper sees more sense in Teva buying Perrigo than Mylan
Piper Jaffray says that while a potential acquisition of Mylan (MYL) by Teva (TEVA) would bring major cost synergies and meaningful earnings accretion, it would not significantly improve the limited visibility on long-term top-line and earnings growth for Teva. Piper sees more strategic sense in Teva acquiring Perrigo (PRGO). Such a deal would drive multiple expansion for Teva since Perrigo's Consumer Health and Nutritionals businesses can offer a "much higher level of visibility on robust long-term earnings growth" than what Mylan can offer Teva, Piper tells investors today. The firm reiterates a Neutral rating on shares of Teva.
07:14 EDTMYLTeva Mylan deal more likely to get done than Mylan Perrigo deal,says Wells Fargo
Subscribe for More Information
07:00 EDTMYLPerrigo price target raised to $203 from $187 at Jefferies
Jefferies raised its price target for Perrigo (PRGO) to $203 after the company rejected Mylan's (MYL) takeover bid of $205 per share. The firm believes Perrigo "left the door wide open" for a higher, more definitive bid. It sees a 40% chance of either Mylan or another suitor acquiring Perrigo. The firm keeps a Buy rating on the stock.
06:59 EDTHBANHuntington Bancshares reports Q1 EPS 19c, consensus 19c
Reports Q1 revenue $706.9M, consensus $712.62M. Reports Q1 loan loss provision $21M vs. $24.63M a year ago. Reports Q1 net charge-offs $24.4M vs. $42.99M a year ago.
06:31 EDTMYLMylan likely to improve offer for Perrigo, says Citigroup
Citigroup believes Mylan's (MYL) board will likely reject Teva's (TEVA) initial takeover offer of $82 per share and present an improved proposal to acquire Perrigo (PRGO). Citi continues see a potential Teva-Mylan combination as more value accretive for Mylan shareholders than a potential Mylan-Perrigo combination. It keeps a Neutral rating on Mylan.
06:30 EDTMYLMylan shareholders urge board to consider Teva offer, Reuters reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use